Parkinson’s disease, the second most common neurodegenerative disease after Alzheimer’s, is a progressive movement disorder characterized by rigidity, tremors, and postural instability. The pathological hallmarks of PD are progressive loss of dopaminergic neurons in the substantia nigra of the ventral midbrain and the presence of intracellular Lewy bodies in surviving neurons of the brain stem. Research studies have shown various genes and loci are genetically linked to PD including α-synuclein/PARK1 and 4, parkin/PARK2, UCH-L1/PARK5, PINK1/PARK6, DJ-1/PARK7, LRRK2/PARK8, synphilin-1, and NR4A2.Leucine-rich repeat kinase 2 contains amino-terminal leucine-rich repeats, a Ras-like small GTP binding protein-like domain, an MLK protein kinase domain, and a carboxy-terminal WD40 repeat domain. Research studies have linked at least 20 LRRK2 mutations to PD, with the G2019S mutation being the most prevalent. The G2019S mutation causes increased LRRK2 kinase activity, which induces a progressive reduction in neurite length that leads to progressive neurite loss and decreased neuronal survival. Researchers are currently testing the MLK inhibitor CEP-1347 in PD clinical trials, indicating the potential value of LRRK2 as a therapeutic target for treatment of PD.
[1] Fahn, S. (2003) Ann. NY Acad. Sci. 991, 1-14.
[2] Moore, D.J. et al. (2005) Annu. Rev. Neurosci. 28, 57-87.
[3] Mata, I.F. et al. (2006) Trends Neurosci. 29, 286-293.
[4] MacLeod, D. et al. (2006) Neuron 52, 587-593.
[5] Parkinson Study Group. (2004) Neurology 62, 330-332.
